A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis

被引:69
作者
Derk, Chris T. [1 ]
Grace, Elizabeth [1 ]
Shenin, Max [1 ]
Naik, Manisha [1 ]
Schulz, Steffan [1 ]
Xiong, Wen [1 ]
机构
[1] Thomas Jefferson Univ, Div Rheumatol, Philadelphia, PA 19107 USA
关键词
Mycophenolate mofetil; Mycophenolic acid; Fibrosis; Systemic sclerosis; Scleroderma; Treatment; D-PENICILLAMINE; SCLERODERMA; CYCLOPHOSPHAMIDE; THERAPY;
D O I
10.1093/rheumatology/kep295
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To evaluate the efficacy and safety of mycophenolate mofetil for the treatment of SSc. Methods. We recruited 15 patients with dcSSc to take part in an open-label study using mycophenolate mofetil to treat their disease over a 12-month period. The primary outcome measure was the modified Rodnan skin score (mRSS), whereas secondary outcomes included the Medsger severity score, pulmonary function studies, 2D echocardiograms and the Short Form Health Survey (SF)-36 questionnaire. Results. The mRSS significantly improved in those patients who tolerated the medication for > 3 months (P < 0.0001), and there was a statistically significant improvement in the Medsger severity scores of the general (P = 0.05), peripheral vascular involvement (P = 0.05) and skin (P = 0.0003) scores. The SF-36 scores improved (P = 0.05) and the pulmonary function studies showed a trend towards improvement, though not of statistical significance. The mean pulmonary artery pressure by 2D echocardiography did not change. Conclusions. In this prospective open-label study of mycophenolate mofetil for the treatment of dcSSc, we observed significant improvements in skin scores, peripheral vascular involvement and patient-perceived health status. Pulmonary function studies did not worsen as expected, but instead showed a trend towards improvement. Controlled trials are needed to further investigate this trend for improved pulmonary function studies.
引用
收藏
页码:1595 / 1599
页数:5
相关论文
共 50 条
[31]   Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial [J].
Gaubitz, M ;
Schorat, A ;
Schotte, H ;
Kern, P ;
Domschke, W .
LUPUS, 1999, 8 (09) :731-736
[32]   BOSENTAN TREATMENT FOR RAYNAUD'S PHENOMENON AND SKIN FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS AND PULMONARY ARTERIAL HYPERTENSION: AN OPEN-LABEL, OBSERVATIONAL, RETROSPECTIVE STUDY [J].
Giordano, N. ;
Puccetti, L. ;
Papakostas, P. ;
Di Pietra, N. ;
Bruni, F. ;
Pasqui, A. L. ;
Acampa, M. ;
Bocchi, V. ;
Donati, V. ;
Voglino, M. ;
Fioravanti, A. ;
Montella, A. ;
Auteri, A. ;
Nuti, R. ;
Pastorelli, M. .
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2010, 23 (04) :1185-1193
[33]   Efficacy and safety of oral cyclophosphamide versus mycophenolate mofetil in childhood nephrotic syndrome: an open-label comparative study [J].
Dhooria, Gurdeep Singh ;
Bhargava, Siddharth ;
Bhat, Deepak ;
Pooni, Puneet Aulakh ;
Goel, Nancy ;
Kakkar, Shruti .
BMC NEPHROLOGY, 2024, 25 (01)
[34]   Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial [J].
Kuhn, Annegret ;
Haust, Merle ;
Ruland, Vincent ;
Weber, Ramona ;
Verde, Pablo ;
Felder, Gerd ;
Ohmann, Christian ;
Gensch, Kristina ;
Ruzicka, Thomas .
RHEUMATOLOGY, 2010, 49 (07) :1336-1345
[35]   BAricitinib in patients with SystemIC Sclerosis (BASICS): a prospective, open-label, randomised trial [J].
Chen, Fangfang ;
Ye, Wenjing ;
Wang, Qian ;
Zhao, Li ;
Liang, Minrui ;
Zheng, Shucong ;
Zhao, Tianyi ;
Xuan, Dandan ;
Zhu, Zaihua ;
Yu, Yiyun ;
Kong, Ning ;
Jiang, Li ;
Yang, Xue ;
Zhu, Xiaoxia ;
Wan, Weiguo ;
Zou, Hejian ;
Xue, Yu .
CLINICAL RHEUMATOLOGY, 2025,
[36]   Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study [J].
Roland, M. ;
Barbet, C. ;
Paintaud, G. ;
Magdelaine-Beuzelin, C. ;
Diot, E. ;
Halimi, J. M. ;
Lebranchu, Y. ;
Nivet, H. ;
Buechler, M. .
LUPUS, 2009, 18 (05) :441-447
[37]   A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis [J].
Vanthuyne, M. ;
Blockmans, D. ;
Westhovens, R. ;
Roufosse, F. ;
Cogan, E. ;
Coche, E. ;
Toukap, A. Nzeusseu ;
Depresseux, G. ;
Houssiau, F. A. .
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2007, 25 (02) :287-292
[38]   Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis [J].
Ueda, Takahiro ;
Sakagami, Takuro ;
Kikuchi, Toshiaki ;
Takada, Toshinori .
RESPIRATORY INVESTIGATION, 2018, 56 (01) :14-20
[39]   Mycophenolate Mofetil for Induction and Maintenance of Remission in Microscopic Polyangiitis with Mild to Moderate Renal Involvement-A Prospective, Open-Label Pilot Trial [J].
Silva, Francisco ;
Specks, Ulrich ;
Kalra, Sanjay ;
Hogan, Marie C. ;
Leung, Nelson ;
Sethi, Sanjeev ;
Fervenza, Fernando C. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (03) :445-453
[40]   A Real-World Experience of Mycophenolate Mofetil for Systemic Sclerosis: A Retrospective Multicenter Observational Study [J].
Lee, Kyung-Ann ;
Kim, Bo Young ;
Choi, Sung Jae ;
Kim, Seong-Kyu ;
Kim, Sang-Hyon ;
Kim, Hyun-Sook .
ARCHIVES OF RHEUMATOLOGY, 2020, 35 (03) :366-375